Differential evaluation of autoimmune liver disease of unknown etiology, especially autoimmune hepatitis (AIH) of childhood onset. Use in combination with Liver Cytosolic Antigen Type 1 (LC-1) Antibody, IgG (2010711) when evaluating for AIH-2.
EPIC code
LAB3262
Collect
Serum separator tube.
Specimen Preparation
Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Storage/Transport Temperature
Refrigerated.
Stability (from collection to initiation)
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month.
Liver-Kidney Microsome IgG antibody (anti-LKM), as detected by indirect immunofluorescent antibody (IFA) techniques, may be observed in patients with autoimmune hepatitis type 2 (AIH-2), AIH-2 associated with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), viral hepatitis C or D, and some forms of drug-induced hepatitis. This IFA does not differentiate among the four types of LKM antibodies (LKM-1, LKM-2, LKM-3, and a fourth type that recognizes CYP1A2 and CYP2A6 antigens). Of these, anti-LKM-1 (cytochrome P450IID6) IgG antibodies are considered specific for AIH-2.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Lab Test Information
Ordering Recommendations
Differential evaluation of autoimmune liver disease of unknown etiology, especially autoimmune hepatitis (AIH) of childhood onset. Use in combination with Liver Cytosolic Antigen Type 1 (LC-1) Antibody, IgG (2010711) when evaluating for AIH-2.
EPIC code
LAB3262
Collect
Serum separator tube.
Specimen Preparation
Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Storage/Transport Temperature
Refrigerated.
Stability (from collection to initiation)
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month.
Liver-Kidney Microsome IgG antibody (anti-LKM), as detected by indirect immunofluorescent antibody (IFA) techniques, may be observed in patients with autoimmune hepatitis type 2 (AIH-2), AIH-2 associated with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), viral hepatitis C or D, and some forms of drug-induced hepatitis. This IFA does not differentiate among the four types of LKM antibodies (LKM-1, LKM-2, LKM-3, and a fourth type that recognizes CYP1A2 and CYP2A6 antigens). Of these, anti-LKM-1 (cytochrome P450IID6) IgG antibodies are considered specific for AIH-2.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratories.